Literature DB >> 21457447

Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.

Sabine Irtan1, Xavier Chopin-Laly, Maxime Ronot, Sandrine Faivre, Valérie Paradis, Jacques Belghiti.   

Abstract

We report two cases of locally advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT) who complete regression by sorafenib treatment allowed curative resection. Two male adult (59 and 57 years) cirrhotic patients with HCC associated with PVTT including one with lymph node involvement had elevated α-fetoprotein level (AFP) (867 and 17 000) and were treated with standard sorafenib treatment during 10 and 12 months respectively. Size decrease of the main tumour, disappearance of PVTT and normalization of AFP allowed curative surgical resection. No viable tumour cells were found in the specimen and the two patients are currently alive without recurrence 12 and 16 months after surgery. These first two cases of complete tumour necrosis after sorafenib treatment allow us to reconsider surgical treatment in patients with unresectable HCC responding to this medical treatment.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21457447     DOI: 10.1111/j.1478-3231.2010.02441.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  30 in total

1.  Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.

Authors:  Hai-Hong Ye; Jia-Zhou Ye; Zhi-Bo Xie; Yu-Chong Peng; Jie Chen; Liang Ma; Tao Bai; Jun-Ze Chen; Zhan Lu; Hong-Gui Qin; Bang-De Xiang; Le-Qun Li
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

2.  Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma.

Authors:  Ryota Matsuki; Kirio Kawai; Yutaka Suzuki; Masaharu Kogure; Tetsuya Nakazato; Daisuke Naruge; Naohiro Okano; Satowa Seki; Yoshihiko Ohmori; Naohiro Kawamura; Hiroshi Kamma; Tadakazu Hisamatsu; Junji Shibahara; Toshiyuki Mori; Junji Furuse; Yoshihiro Sakamoto
Journal:  Liver Cancer       Date:  2020-03-05       Impact factor: 11.740

3.  Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.

Authors:  Sun Young Ahn; Hyun Seok Lee; Young Oh Kweon; Won Young Tak; Soo Young Park
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

Review 4.  Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis.

Authors:  Yu Zhang; Zhi-Long Shi; Xia Yang; Zheng-Feng Yin
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

5.  Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.

Authors:  Jung Gil Park; Soo Young Park; Hye Won Lee
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

6.  Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.

Authors:  Hong-Bo Huan; Wan-Yee Lau; Feng Xia; Kuan-Sheng Ma; Ping Bie
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

7.  Modulatory effect of luteolin on redox homeostasis and inflammatory cytokines in a mouse model of liver cancer.

Authors:  Qiang Zhang; Jie Yang; Jun Wang
Journal:  Oncol Lett       Date:  2016-10-19       Impact factor: 2.967

8.  Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.

Authors:  Hideaki Takeyama; Toru Beppu; Takaaki Higashi; Takayoshi Kaida; Kota Arima; Katsunobu Taki; Katsunori Imai; Hidetoshi Nitta; Hiromitsu Hayashi; Shigeki Nakagawa; Hirohisa Okabe; Daisuke Hashimoto; Akira Chikamoto; Takatoshi Ishiko; Motohiko Tanaka; Yutaka Sasaki; Hideo Baba
Journal:  Surg Today       Date:  2017-11-07       Impact factor: 2.549

9.  Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.

Authors:  Toshihiro Kitajima; Etsuro Hatano; Yusuke Mitsunori; Kojiro Taura; Yasuhiro Fujimoto; Masaki Mizumoto; Hideaki Okajima; Toshimi Kaido; Sachiko Minamiguchi; Shinji Uemoto
Journal:  Clin J Gastroenterol       Date:  2015-08-07

10.  Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.

Authors:  Akihiro Yamasaki; Narihiro Umeno; Shigeru Harada; Kosuke Tanaka; Masaki Kato; Kazuhiro Kotoh
Journal:  J Gastrointest Oncol       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.